In an order entered on August 21, 2020 in the Zetia (Ezetimibe) Antitrust Litigation MDL, Senior United States District Judge Rebecca Beach Smith overruled Defendants’ objections and adopted and approved in full United States Magistrate Judge Douglas E. Miller’s prior Report and Recommendation proposing to certify a 35-member class of Zetia direct purchasers.
Zetia is a brand pharmaceutical drug indicated to reduce blood cholesterol levels marketed in the United States by Merck & Co., Inc. Plaintiffs in the MDL allege that Merck conspired with its ostensible generic competitors Glenmark Pharmaceuticals Inc., USA to forestall generic competition and thereby preserve billions of dollars in annual Zetia brand sales for several years.
Faruqi and Faruqi, LLP is one of the leading firms representing the direct purchaser class plaintiffs in the MDL.
About Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP focuses on complex civil litigation, including securities, antitrust, wage and hour, personal injury and consumer class actions as well as shareholder derivative and merger and transactional litigation. The firm is headquartered in New York, and maintains offices in California, Delaware, Georgia and Pennsylvania.
Since its founding in 1995, Faruqi & Faruqi, LLP has served as lead or co-lead counsel in numerous high-profile cases which ultimately provided significant recoveries to investors, direct purchasers, consumers and employees.
To schedule a free consultation with our attorneys and to learn more about your legal rights, call our offices today at (877) 247-4292 or (212) 983-9330.
About Bradley J. Demuth
Bradley J. Demuth's practice is focused on complex antitrust litigation with particular expertise in cases involving pharmaceutical overcharges resulting from delayed generic entry schemes, price fixing, and other anticompetitive conduct. Brad is a partner in the firm's New York office.